Ida Kuhlmann

Ida Kuhlmann

Auto-generated profile, based on publicly available information

Ida Kuhlmann

Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark Odense Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2017 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
PDF file
MHMorten Rix Hansen
Morten Rix Hansen
IKIda Berglund Kuhlmann
Ida Berglund Kuhlmann
APAnton Pottegård
Anton Pottegård
PDPer Damkier
Per Damkier
Venlafaxine is a commonly used antidepressant agent. We aimed to provide detailed information on the associations between venlafaxine dose and concentrations of venlafaxine, by patient age and sex. From a therapeutic drug monitoring (TDM) database located at Odense University Hospital, Denmark, we identified all adults for whom the treating physician had requested clinical advice on the TDM result for venlafaxine between 2002 and 2012. We identified 1077 TDM samples of venlafaxine from 334 males and 743 females (median age 45 years), and the median daily dose was 225 mg. Median plasma concentration of venlafaxine and o‐desmethylvenlafaxine (ODV) was 306 nmol/L and 861 nmol/L, respectively. The median dose‐corrected serum level for venlafaxine was 1.49 nmol/L/mg., while the dose‐corrected serum level of men and women were 1.21 nmol/L/mg and 1.60 nmol/L/mg, respectively. The dose‐corrected sum of venlafaxine and ODV was 8.91 nmol/L/mg (IQR 6.56–12.26) versus 5.52 nmol/L/mg (IQR 4.16–7.52) for patients above 64 years and below the age of 65 years, respectively. Dose‐corrected plasma concentrations of venlafaxine and ODV are increased to a clinically significant degree in patients above the age of 64, and initiation of venlafaxine therapy in the elderly should be made cautiously and supported by drug measurements.

28 October 2020 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
IKIda Kuhlmann
Ida Kuhlmann
SPSidsel Arnspang Pedersen
Sidsel Arnspang Pedersen
PEPeter Skov Esbech
Peter Skov Esbech
TSTore Bjerregaard Stage
Tore Bjerregaard Stage
MCMette Marie Hougaard Christensen
Mette Marie Hougaard Christensen
KBKim Brøsen
Kim Brøsen

16 July 2021 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
IKIda Kuhlmann
Ida Kuhlmann
ANAmanda Nøddebo Nyrup
Amanda Nøddebo Nyrup
TSTore Bjerregaard Stage
Tore Bjerregaard Stage
MCMette Marie Hougaard Christensen
Mette Marie Hougaard Christensen
TBTroels Korshøj Bergmann
Troels Korshøj Bergmann
KBKim Brøsen
Kim Brøsen
The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive on four separate occasions A: A tablet metformin (1 g), B: Metformin (0.5 g) intravenously, C: Five doses of tablet codeine 25 mg; the last dose was administered together with a tablet metformin (1 g), D: Five doses of tablet codeine 25 mg; the last dose was administered together with metformin (0.5 g) intravenously. Blood samples were drawn for 24 hours after administration of metformin, and for 6 hours after administration of codeine and analyzed using liquid chromatography and tandem mass spectrometry (LC-MS/MS). Healthy volunteers genotyped as CYP2D6 normal metabolizers (*1/*1) without known reduced function variants in the OCT1 gene (rs12208357, rs34130495, rs34059508, rs72552763) were invited. The median absorption fraction of metformin was 0.31 and was not influenced by codeine intake. The median Tmaxafter oral intake of metformin was 2 hours without, and 3 hours with codeine (p=0.06). The geometric mean ratios of the AUCs for morphine and its metabolites M3G and M6G for oral intake of metformin-to-no metformin were 1.21, 1.31 and 1.27, respectively, and for intravenous metformin-to-no metformin 1.28, 1.34 and 1.30. Concomitant oral and iv metformin increased the plasma levels of morphine, M3G and M6G. These small pharmacokinetic changes may well contribute to an increased risk of early discontinuation of metformin. Hence, a clinically relevant drug-drug interaction between metformin and codeine seems plausible.

2 October 2021 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
PDF file
IKIda Kuhlmann
Ida Kuhlmann
RPRasmus Hjelmar Petersen
Rasmus Hjelmar Petersen
MOMorten Overgaard
Morten Overgaard
KCKenn Dornonville de la Cour
Kenn Dornonville de la Cour
SZStine Zwisler
Stine Zwisler
KBKim Brøsen
Kim Brøsen
We investigated the impact of genetic variants in OCT1 (SLC22A1) on morphine, morphine‐3‐glucuronide (M3G) and morphine‐6‐glucuronide (M6G) pharmacokinetics in adult patients scheduled for major surgery. Blood samples were taken before and 5, 10, 15, 30, 45, 60 and 90 min after a bolus of morphine (0.15 mg/kg). Patients were genotyped for the genetic variants (rs12208357, rs34059508, rs72552763 and rs34130495) in OCT1.Eighty‐six patients completed the trial. The mean difference (95% confidence interval) for dose adjusted morphine, M3G and M6G AUC was 0.9 (−0.7–2.4), −5.9 (−11.8 to −0.03) and −1.1 (−2.5–0.4) h/L*10−6, respectively, in patients with two reduced function alleles compared to patients with no reduced function alleles in OCT1. Accordingly, the (AUCM3G/Dose)/(AUCmorphine/Dose) and (AUCM6G/Dose)/(AUCmorphine/Dose) ratio was reduced, −1.8 (−3.2 to −0.4) and −0.4 (−0.7 to −0.03), respectively, when comparing the same groups. OCT1 variants had no influence on the experience of pain, adverse events or the number of PCA doses used. In conclusion, genetic variants in OCT1 had a small and clinically unimportant impact on the exposure of morphine after intravenous administration. Our results do not support pre‐emptive genotyping for OCT1 prior to morphine administration in patients scheduled for major surgery.